Old mate, tread lightly as you know we currently sit in a different place to previous trials. No further work Announcements eg another Phase 2 trial or further mouse studies.
Only further analysis ticking off the questions from the big boy's.
View attachment 1552513
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372075
Trial still open with no journal published.
100mg data kept save.
Assay name that tested the latent reservoir still not released in fear from them getting
stalked by LTH.
No real data released other then D's head.
And the sleeping giant that has been over looked
Patent for Influenza
However, the present application surprisingly shows that
BIT225 has activity against multiple subtypes and strains of influenza virus. Importantly, BIT225 has been found to have activity against subtypes and strains that are resistant to amantadine.
[0018] The chemical structure of BIT225 is shown below:
[0019] BIT225 may also be referred to as N-carbamimidoyl-5-(1-methylpyrazol-4-yl)naphthalene-2-carboxamide or 5-(1-methylpyrazol-4-yl)2-naphthoylguanidine.
[0020] The present invention generally relates to the use of BIT225, or a pharmaceutically acceptable salt thereof, for
treating or preventing influenza, for
inhibiting the replication of influenza virus, for reducing the severity, intensity, or duration of complications or symptoms associated with influenza, or for
reducing the titre of influenza virus.
https://patentscope2.wipo.int/searc...145148&tab=PCTDESCRIPTION&maxRec=1000
We sit here with patience, I am sure you will catch on the way up.
